 |
|
|
| |
Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration
|
| |
| |
Pharm: Cabotegravir Long-Acting (LA) Injectable Nanosuspension - (06/16/15)
Reported by Jules Levin
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy
Washington, DC
June 8-10, 2016
S.L. Ford1, K. Sutton2, Y. Lou1, J. Zhang3, A. Tenorio2, C. Trezza2, P. Patel4, W. Spreen2
1Paraxel, Clinical Development, Durham, USA; 2ViiV Healthcare, Clinical Development, Research Triangle Park, USA; 3Paraxel, Biostatistics, Durham, USA; 4ViiV Healthcare, Clinical Pharmacology, Research Triangle Park, USA
|
| |
|
|
|
|
|
